As part of our strategic commitment to innovation and development, Pharmazac participates in the project:
“Reform of the clawback system and its offsetting with research and investment expenditures”, implemented under the National Recovery and Resilience Plan – Greece 2.0, with the General Secretariat for Research and Innovation / Ministry of Development as the implementing authority.
This project aims to effectuate the digital and productive transformation of the pharmaceutical sector by offsetting automatic pharmaceutical expenditure returns with research and investment outlays.
Pharmazac’s investment is implemented through the following three complementary projects:
| Project Title | Total Budget | EU Contribution |
|---|---|---|
| R&D of Generic and Originator Pharmaceutical Products (TACL1) | €5,171,081.00 | €3,102,648.60 |
| Construction of a New Pharmaceutical Manufacturing Plant within the Keratea Industrial Park (BIO.PA) (TACL2) | €8,130,000.00 | €2,845,500.00 |
| R&D Project for Generic and Innovative Pharmaceutical Products in Keratea (2024–2025) (TACL3) | €4,524,600.00 | €2,714,760.00 |
The total budget of the investment amounts to €17.825.681,00 of which the public expenditure stands at €8.662.908,60 and is funded by the European Union – NextGenerationEU under the auspices of the National Recovery and Resilience Plan “Greece 2.0”.
The business plan encompasses investments in the following categories:
- Development of human-use pharmaceutical products and regulatory dossiers
- Construction and operation of a solid-form pharmaceutical manufacturing facility in Keratea
The aim of the project is to strengthen Pharmazac’s research and production capacity, promote innovation, and enhance competitiveness in the pharmaceutical sector.
Pharmazac has received funding for the implementation of these actions through the European Union, under the NextGenerationEU initiative, strengthening our research and production capabilities.
